No easy way out for Abbott as deal target faces bribery probe
Minneapolis
ABBOTT Laboratories tried to end its US$5.8 billion agreement to buy Alere Inc after finding out in mid- March that the medical-testing company was swept up in a US probe of bribery overseas. Alere's shares, meanwhile, are trading at levels suggesting that investors have their doubts about the transaction - at least at the current price.
Not so fast, legal experts and analysts say. Violations of the US Foreign Corrupt Practices Act, or FCPA, aren't necessarily a deal-breaker and with Alere refusing to go away, Abbott may have no easy way out.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue